Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Annachiara Uccellatore, Stefano Genovese, Ilaria Dicembrini, Edoardo Mannucci, Antonio Ceriello

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

Original languageEnglish
Pages (from-to)239-256
Number of pages18
JournalDiabetes Therapy
Volume6
Issue number3
DOIs
Publication statusPublished - Sep 26 2015

Fingerprint

Glucagon-Like Peptide 1
Metformin
Hypoglycemia
Type 2 Diabetes Mellitus
Weight Gain
Glucagon-Like Peptide-1 Receptor
exenatide
Therapeutics
ZP10A peptide
Liraglutide
rGLP-1 protein
dulaglutide

Keywords

  • GLP-1 RAs
  • Glucagon-like peptide-1 receptor agonists
  • Incretin
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. / Uccellatore, Annachiara; Genovese, Stefano; Dicembrini, Ilaria; Mannucci, Edoardo; Ceriello, Antonio.

In: Diabetes Therapy, Vol. 6, No. 3, 26.09.2015, p. 239-256.

Research output: Contribution to journalArticle

@article{f977cc9b2966426595574662a8de9382,
title = "Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists",
abstract = "Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.",
keywords = "GLP-1 RAs, Glucagon-like peptide-1 receptor agonists, Incretin, Type 2 diabetes mellitus",
author = "Annachiara Uccellatore and Stefano Genovese and Ilaria Dicembrini and Edoardo Mannucci and Antonio Ceriello",
year = "2015",
month = "9",
day = "26",
doi = "10.1007/s13300-015-0127-x",
language = "English",
volume = "6",
pages = "239--256",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "3",

}

TY - JOUR

T1 - Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

AU - Uccellatore, Annachiara

AU - Genovese, Stefano

AU - Dicembrini, Ilaria

AU - Mannucci, Edoardo

AU - Ceriello, Antonio

PY - 2015/9/26

Y1 - 2015/9/26

N2 - Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

AB - Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes Association and European Association for the Study of Diabetes recommend GLP1-RAs as add-on to metformin when therapeutic goals are not achieved with monotherapy, particularly for patients who wish to avoid weight gain or hypoglycemia. GLP1-RAs differ substantially in their duration of action, frequency of administration and clinical profile. Members of this class approved for clinical use include exenatide twice-daily, exenatide once-weekly, liraglutide and lixisenatide once-daily. Recently, two new once-weekly GLP1-RAs have been approved: dulaglutide and albiglutide. This article summarizes properties of short- and long-acting GLP-1 analogs, and provides useful information to help choose the most appropriate compound for individual patients.

KW - GLP-1 RAs

KW - Glucagon-like peptide-1 receptor agonists

KW - Incretin

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84942306927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942306927&partnerID=8YFLogxK

U2 - 10.1007/s13300-015-0127-x

DO - 10.1007/s13300-015-0127-x

M3 - Article

AN - SCOPUS:84942306927

VL - 6

SP - 239

EP - 256

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 3

ER -